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Abstract: AICAR (5-Aminoimidazole-4-carboxamide-1-beta-D-ribofuranosyl 5'-
monophosphate) is a natural metabolic intermediate of purine biosynthesis that is present 
in all organisms. In yeast, AICAR plays important regulatory roles under physiological 
conditions, notably through its direct interactions with transcription factors. In humans, 
AICAR accumulates in several metabolic diseases, but its contribution to the symptoms 
has not yet been elucidated. Further, AICAR has highly promising properties which have 
been recently revealed. Indeed, it enhances endurance of sedentary mice. In addition, it has 
antiproliferative effects notably by specifically inducing apoptosis of aneuploid cells. Some 
of the effects of AICAR are due to its ability to stimulate the AMP-activated protein kinase 
but some others are not. It is consequently clear that AICAR affects multiple targets 
although only few of them have been identified so far. This review proposes an overview 
of the field and suggests future directions. 
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1. Introduction 
AICAR (5-Aminoimidazole-4-carboxamide-1-β-D-ribofuranosyl 5'-monophosphate), also known as 
ZMP (the “Z” referring to imidaZole [1]), is an intermediate in the inosine monophosphate (IMP) 
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conserved pathway which is responsible for de novo purine biosynthesis in all organisms. The recent 
attention paid to AICAR is testified by more than one thousand publications referenced in databases 
such as PubMed, 90% of which having been published during the last 10 years. This massive and 
sustained interest for this small molecule is due to its multiple biological effects, which will be 
presented in this review. 
2. Metabolism of AICAR 
AICAR is an intermediate metabolite in the purine de novo synthesis pathway (Figure 1), it is 
synthesized from succinyl-AICAR (SAICAR) by adenylosuccinate lyase (ASL), an enzyme inhibited 
by AICAR through a feedback regulation [2]. As a consequence, massive accumulation of AICAR is 
associated with SAICAR accumulation in micro-organisms such as yeast [3] and in a specific human 
pathology [4]. In the de novo purine synthesis pathway, AICAR is further metabolized to IMP by 
successive action of AICAR-Transformylase and IMP Cyclohydrolase, two enzymatic activities which 
are generally carried on a single protein named ATIC. In micro-organisms, AICAR is also synthesized 
as a by-product of the histidine biosynthesis pathway (Figure 1).  
Figure 1. Schematic representation of the de novo purine and histidine pathways in yeast. 
AICAR: 5-Aminoimidazole-4-carboxamide-1-β-D-ribofuranosyl 5'-monophosphate. 
AICAr: riboside form of AICAR (also named acadesine). AMP: Adenosine 5'-
monophosphate; GMP: Guanosine 5'-monophosphate; IMP: Inosine 5'-monophosphate. 
PRFAICAR: 5-(5-Phospho-D-ribosylaminoformimino)-1-(5-phosphoribosyl)-imidazole-4-
carboxamide. SAICAR: succinyl-AICAR. SAICAr: succinyl-AICAr. ZMP: AICAR 
monophosphate. ZTP: AICAR triphosphate. Enzyme names are given in blue. Question 
marks indicate enzymatic activities catalyzed by unidentified enzymes.  
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Under conditions where AICAR accumulates, riboside and triphosphate derivatives are often found 
in cellular extracts or body fluids. A patient lacking ATIC activity showed accumulation of large 
amounts of AICAR riboside (also known as acadesine or AICAr) in urines and mono- di- and tri-
phosphate forms of AICAR in erythrocytes [4]. The enzyme(s) dephosphorylating AICAR 
monophosphate to its riboside form is not identified yet, but it is clear that adenosine kinase can 
reverse the reaction and phosphorylate AICAR riboside to the monophosphate form [5]. Synthesis of 
ZTP (triphosphate form of AICAR) was found to occur directly from AICAR through the catalytic 
action of PRPP-synthetase [6]. Consequently, ZDP (diphosphate form of AICAR) detected in 
erythrocytes is likely to result from ZTP degradation and to appear upon intracellular degradation or 
during metabolite extraction, rather than be a ZTP synthesis intermediate. In the early eighties, ZTP 
was proposed to be an “alarmone” signaling folate deficiency in Salmonella typhimurium [1] but a 
later study did not confirm such a role for ZTP in Escherichia coli [7].  
3. Roles of Physiologically Produced AICAR and Accumulation in Metabolic Diseases 
A physiological role for AICAR has been found in yeast cells where it stimulates the interaction 
between two pairs of transcription factors (Bas1-Pho2 and Pho4-Pho2), thereby resulting in the 
transcriptional activation of specific sets of genes [3,8]. Importantly, most of the AICAR-responsive 
genes also respond to extracellular adenine, their expression being low when adenine is abundant in 
the growth medium [3,9–14]. AICAR concentration is linked to exogenous adenine through feedback 
regulation of the first step of the purine de novo pathway. This feedback regulation is thought to be 
mediated by ATP and ADP [2]. Consistently, in adenine replete conditions, ADP and ATP 
concentrations are higher [12], while AICAR concentration decreases [15]. Finally, fusion chimera 
between AICAR-stimulated transcription factors resulted in an adenine-independent transcriptional 
activation of the target genes [3,16]. These results led to a model accounting for the complex 
regulatory effects of AICAR in yeast and their connection to purine precursor availability in the 
growth medium (Figure 2). Beside these physiological effects associated to moderate AICAR 
accumulation, massive accumulation of AICAR can also lead to detrimental effects in yeast. 
Intracellular accumulation of AICAR in the millimolar range provokes histidine auxotrophy and, when 
combined to the fau1 mutation affecting 5,10-methenyltetrahydrofolate synthetase, leads to methionine 
auxotrophy. Higher concentrations, up to 10-15 mM, result in growth arrest [15]. In yeast, 
physiological and detrimental effects of AICAR are only associated to its phophorylated form(s), since 
accumulation of the riboside form at the same concentration has no effects either on transcription, 
amino-acids prototrophy nor on cellular growth [15]. 
In mammalian cells it is not known whether endogenous AICAR plays regulatory roles. It is 
however striking that most purine metabolism-associated diseases result in AICAR accumulation in 
the patient cells [17]. The most dramatic accumulation of AICAR was observed in the erythrocytes of 
an ATIC-deficient patient and was associated to dysmorphic features, severe neurological defects, and 
congenital blindness [4]. At this point it is not clear whether some or all of these symptoms are the 
direct result of very high AICAR concentrations or whether they are due to the increase of AICAR 
derivatives and/or to the severe ATP depletion associated with AICAR massive accumulation [4]. The 
consequences of AICAR accumulation in other purine metabolism-associated diseases is not 
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established, but AICAR was proposed as the possible toxic metabolite in Lesch-Nyhan disease 
resulting from impaired hypoxanthine-guanine phosphoribosyl transferase [18]. 
Figure 2. Schematic representation of AICAR physiological effects in yeast. Intracellular 
ATP and AICAR concentrations were determined by liquid chromatography as described 
in [19] on exponentially BY4741 cells grown in SD medium containing 1% casaminoacid 
(Difco), tryptophan (0.2 mM) and containing (upper panel) or not (lower panel) adenine 
(0.3 mM). ADE and PHO genes refer to Bas1-Pho2 and Pho4-Pho2 target genes, 
respectively. 
 
4. AICAR, a Potent Activator of AMP-Activated Protein Kinase 
In the early 90s, AICAR in its monophosphate form was found to activate the human AMP-
activated protein kinase (AMPK) activity in vitro [20]. The AICAR riboside precursor was then used 
to activate AMPK in isolated rat adipocytes [21]. Since then, AICAR has been used in hundreds of 
studies as an inducer of AMPK activity. A major advantage of AICAR compared to other AMPK-
inducers is that AICAR addition at low concentration (< 500 µM) does not affect AMP, ADP or ATP 
levels [22]. However, more recently, effects of AICAR on ATP concentration were reported in rat 
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hepatocytes [23,24]. This observation combined with the multiple AMPK-independent effects reported 
for AICAR (see below) should inspire cautious interpretation of the results (as discussed in [25]). 
AICAR was found to directly interact with the gamma-subunit of AMPK. This interaction induces a 
conformational change and favors phosphorylation of the catalytic alpha subunit, which in turn 
becomes more active. Structural analysis of the AMPK-AICAR complex suggests that activation of 
this protein kinase by AICAR mimics activation by AMP [26]. Hence, the effect of AICAR on AMPK 
is presumed to be direct.  
AICAR monophosphate is provided to the cells as a riboside precursor, which is taken up by 
adenosine transporter(s) [27]. In many studies, the authors use an inhibitor of adenosine kinase to show 
that AICAR monophosphate, and not its riboside precursor, is the active molecule (Figure 3) [28]. 
Among the effects attributed to AICAR monophosphate, many are AMPK-dependent as shown by si- 
or sh-RNA gene silencing of the gamma-subunits (see Figure 3). For instance the potent effect of 
AICAR on induction of apoptosis in aneuploid cells was abolished by shRNA on AMPK, however it 
was poorly mimicked by other AMPK inducers such as metformin or 2-deoxyglucose [29]. This 
example illustrates the complexity of AICAR effects and calls attention to the fact that a careful 
analysis is required to establish whether an AICAR effect is fully AMPK-dependent or not. 
Figure 3. Schematic depiction of AICAR cellular targets and associated biological effects. 
CML: Chronic myeloid leukemia. CLL: Chronic lymphocytic leukemia. PKC: Protein 
kinase C. Ryr1: Ryanodine receptor 1. All targets and biological effects presented are 
described in [29–36]. 
 
5. AMPK-Independent Effects of AICAR: Other Protein Targets 
It should be stressed that there is a growing number of examples where AICAR effects are totally or 
partially independent of AMPK (Figure 3) [37–40]. It appears more and more evident that AICAR is a 
multi-target molecule resulting in complex and combined effects, in line with the paradigm of 
“network pharmacology” recently proposed by A. Hopkins [41]. For such highly integrated effects, it 
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is critical to apprehend the complexity of the drug effects by identifying its targets. This quest is 
complex because it requires to identify drug-interacting proteins and establish their role in the drug 
action in vivo.  
The use of an AICAR-resin has allowed validating two yeast transcription factors as AICAR-
binders [3]. More recently, affinity chromatography coupled to mass spectrometry allowed us to 
perform a large-scale identification of yeast and mouse AICAR-binders, many of which being 
conserved through species (our unpublished results).  
The next step is to validate the binders as true AICAR targets in vivo. Interestingly, it was recently 
found that the yeast AMPK (Snf1) is activated by ADP but not by AMP [42], thereby accounting for 
the fact that AICAR apparently does not activate the yeast AMPK, as presumed from the transcriptome 
signature [3]. Yeast is therefore an appealing simple eukaryotic model to study AMPK-independent 
AICAR effects. 
Aside from AMPK, AICAR modulates several enzymes such as glucokinase [43] or glycogen 
phosphorylase [44]. In a few cases, direct binding of AICAR to specific proteins has been reported, 
including phosphofructokinase (PFK) and fructose-1,6-biphosphatase (F1,6-BPase) which are 
inhibited in vitro by AICAR [45,46]. AICAR interaction with Hsp90 was also demonstrated and many 
client proteins of Hsp90 were found destabilized in vivo in the presence of AICAR [47]. Both PFK and 
Hsp90 contribute to important functions for tumor growth and could thus be involved in the anti-
proliferative effects of AICAR, which was reported for several tumor cell lines (such as PC-3, MCF-
7,C6 glioma, U87MG, K-562 and CEM) [48]. It is noteworthy that, while AICAR replaces AMP in 
AMPK [26], it competes with ATP in Hsp90 [47]. It will be interesting to determine whether all 
AICAR targets are nucleotide-binding proteins.  
6. Effects of AICAR on Whole Organisms 
There are few studies showing effects of AICAR on whole organisms and in most cases the protein 
effectors are not clearly identified, although AICAR was chosen in these studies for its AMPK-
activating properties.  
AICAR feeding of Caenorhabditis elegans resulted in decreased fat storage as would be predicted 
when AMPK is activated [49]. Drosphila melanogaster fed with AICAR were more resistant to 
anoxia/re-oxygenation injuries [50]. AICAR has been found to reduce myocardial ischemic injury in 
several models (rat, mice, rabbit, dog…) [51] and in humans [52]. Injection of AICAR to mice resulted 
in a hypoglycemic effect [53]. Strikingly, sedentary mice fed with AICAR showed increased 
endurance [54]. AICAR was renamed “the exercise pill” and subsequently suspected of human 
misusage as a doping agent. AICAR is not currently approved by FDA and has only been used in a 
very few investigations in humans [55–57]. 
7. Conclusion  
AICAR is a highly promising pharmacophore showing various effects on multiple functions. In the 
future, AICAR or derivatives could represent key molecules for several diseases including heat 
induced sudden death, cytochrome c-oxidase deficiencies, cancer and other pathologies associated with 
muscle wasting. The systematic identification of AICAR targets is now required to understand the 
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complex consequences resulting, most probably, from synthetic effects on several proteins. 
Importantly, AICAR has both activating and inhibiting effects and hence, determining the way AICAR 
affects each target will require individual characterization. This time consuming process will hopefully 
be made easier by the use of model organisms such as yeast or nematode. 
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